Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Diagnostics » Clinical Sequencing » Perthera's Virtual Molecular Tumor Board Can Improve Patient Outcomes, Overcome Access Barriers

Perthera's Virtual Molecular Tumor Board Can Improve Patient Outcomes, Overcome Access Barriers

Mar 12, 2020
|
Charlotte Hu
Premium

NEW YORK – A new study has demonstrated the utility of an artificial intelligence-powered platform and virtual molecular tumor board by Perthera, a precision oncology firm based in Holliston, Massachusetts, to guide patients to the treatments they're most likely to benefit from.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
17
Featured Webinar

Spatial Profiling of Metabolic Regulation in the Human Tumor Microenvironment Using Multiplexed Ion Beam Imaging

Sponsored by
IONPath

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.

Mar
23
Featured Webinar

ctDNA MRD Detection and Personalized Oncogenomic Analysis in Colorectal Cancer

Sponsored by
Roche

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

Mar
24
Featured Webinar

Single-Cell Analysis and Genome Editing in Preclinical Disease Modeling: Detailed Insights into Leukemia Lineage

Sponsored by
Mission Bio

This webinar, the first in a “Women in Single Cell” series sponsored by Mission Bio, will discuss the use of single-cell analysis to assess genome editing for use in pre-clinical disease modeling.

What's Popular?

In Cancer

  1. Bio-Techne to Acquire Molecular Diagnostics Firm Asuragen for up to $320M

  2. C2i Genomics Acquires Sequencing Lab QNA Dx

  3. Deepcell Advancing AI-Driven Cell Morphology Tech for Single-Cell Genomics, Liquid Biopsy

    Premium

  4. Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience for up to $695M

  5. Agilent Charges Into Liquid Biopsy Space with Resolution Biosciences Acquisition

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.